ADx' latest biomarker P-tau 231 should be of particular interest to immunotherapeutic tau programs, especially for monitoring target engagement.

Eugeen Vanmechelen form ADx will present details of P-tau231 at the upcoming conference of Clinical Trials on Alzjheimer's Disease (CTAD) in San Diego.

A novel conformational, phospho-threonine 231 specific assay for CSF protein tau. (Poster P1-32 on Thursday 8, 2016)

Don't hesitate to contact Eugeen Vanmechelen for any further details: eugeen.vanmechelen@adxneurosciences.com